Alimera Sciences Added To Russell 2000®, 3000® And Global Indexes

      Alimera Sciences Added To Russell 2000®, 3000® And Global Indexes

PR Newswire

ATLANTA, July 1, 2013

ATLANTA, July 1, 2013 /PRNewswire/ --Alimera Sciences, Inc. (NASDAQ: ALIM)
(Alimera), a biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic pharmaceuticals,
announced today that it has been added to the Russell 2000® Index, Russell
3000® Index and Russell Global Index as part of the annual reconstitution by
Russell Investments of its comprehensive set of U.S. and global equity indexes
on June 28, 2013.

"We are pleased to be added to the Russell Global Indexes, and believe our
inclusion will generate further interest among those in the investment
community who may be less familiar with Alimera," said Dan Myers, Alimera's
president and chief executive officer.

Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest
U.S. stocks as of the end of May, ranking them by total market capitalization.
Membership in the Russell 2000 and 3000 remains in place for one year. Russell
determines membership for its equity indexes primarily by objective,
market-capitalization rankings and style attributes.

Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for both passive and active
investment strategies. In the institutional marketplace, an industry-leading
$3.9 trillion in assets currently are benchmarked to them. Based on Russell's
procedures, Alimera will hold its membership until Russell reconstitutes its
indexes in June 2014.

About Alimera Sciences, Inc.
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical
company that specializes in the research, development and commercialization of
prescription ophthalmic pharmaceuticals. Presently, Alimera is focused on
diseases affecting the back of the eye, or retina. Its primary product,
ILUVIEN^®, is an intravitreal implant containing fluocinolone acetonide (FAc),
a non-proprietary corticosteroid with demonstrated efficacy in the treatment
of ocular disease.

Investor Contact:       For press inquiries:
ICR, LLC                Katie Brazel, Fleishman-Hillard
John Mills              for Alimera Sciences
310-954-1105            404-739-0150
John.Mills@icrinc.com  Katie.Brazel@fleishman.com

SOURCE Alimera Sciences, Inc.